Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies.
The use of plasmid DNA as vaccines for the treatment of cancer and infectious diseases is on the rise. In order to facilitate the manufacture of clinical-grade plasmid DNA for Phase I clinical trials, we developed a process whereby >200 mg plasmid could be produced in a single production run under Good Manufacturing Practices. A dedicated cleanroom (Class 10,000 with Class 100 biosafety cabinet) is utilized for production of the bacterial cell bank, fermentation, harvest/lysis of the biomass, and downstream purification. Fermentation requires three 16-18 h runs (approximately 12 L each) in shaker-flasks, yielding approximately 60 g bacterial paste following batch centrifugation. The biomass is alkaline-lysed, pooled, and the resulting flocculent precipitate is separated by a novel vacuum step, followed by depth-filtration. Downstream processing includes anion-exchange chromatography, utilizing Qiagen silica-based resin, and precipitation with isopropanol. Following precipitation, the DNA is harvested by centrifugation, dried, formulated, and sterile-filtered using a Sartorius Sartobran 150 filter prior to Final-Filling. All processing steps utilize sterilized, single-use components. This process results in a product manufactured according to regulatory guidelines. The plasmid DNA is sterile with >or=95% supercoiled DNA, an A260/A280 ratio>or=1.9, undetectable or extremely low residual endotoxin, RNA, genomic DNA, protein, and antibiotic. Residual solvent levels are negligible. The product yields the predicted profile upon restriction-enzyme digestion, is biologically active upon transfection and remains stable for several years at -20 degrees C. We have therefore developed a reproducible and cost effective process to manufacture clinical-grade plasmid DNA. This process can be adapted by other academic centers for human or large animal clinical trials.
Przybylowski
Mark
M
Gene Transfer and Somatic Cell Engineering Facility, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Bartido
Shirley
S
Borquez-Ojeda
Oriana
O
Sadelain
Michel
M
Rivière
Isabelle
I
D000818:Animals; D002482:Cellulose / Q000031:analogs & derivatives; D002852:Chromatography, Ion Exchange; D002874:Chromosome Mapping; D017321:Clinical Trials, Phase I as Topic / Q000592:standards*; D003470:Culture Media; D004247:DNA / Q000032:analysis / Q000096:biosynthesis*; D004345:Drug Industry; D004591:Electrophoresis, Polyacrylamide Gel; D005285:Fermentation; D006801:Humans; D007202:Indicators and Reagents; D010957:Plasmids / Q000235:genetics*; D019444:Vaccines, DNA / Q000032:analysis / Q000096:biosynthesis*
D003470:Culture Media; D007202:Indicators and Reagents; D019444:Vaccines, DNA; C005062:acetylcellulose; D002482:Cellulose; D004247:DNA